Alzheimer’s disease doesn’t have a cure, meaning no treatment can reverse the damage that’s already occurred in the brain.

VERSES AI Inc. (CBOE:VERS) ("VERSES'' or the "Company") a cognitive computing company specializing in next-generation intelligent software systems, announces that on March 27th 2025, the Company's ...

Smithfield Foods, Inc., an American food company and an industry leader in value-added packaged meats and fresh pork, today announced that it has been added to the Russell 1000 Index, a key benchmark ...

The only other drug currently in its pipeline is RVT-104, a combination of glycopyrrolate and high dose rivastigmine, Novartis' off-patent Alzheimer's drug Exelon.

The Dow Jones rose on the stock market today despite President Trump talking on tariffs. A Warren Buffett stock cleared an entry.

The NHS has been good to us. Bill was put on the Exelon drug trial, which is meant to delay the worst parts of the disease. The trial was supervised by a marvellous nurse called Ron Isaacs.

Exelon Corp. (NASDAQ:EXC ... The company’s blockbuster drugs, including Keytruda and Gardasil, contribute significantly to its revenue growth. DBS analyst Nico Chen had reaffirmed a Buy rating ...

Drug manufacturer Gilead rose 17.6% in February ... Regulated electric company Exelon rose 11.5% in February and gained 28.7% over the past 12 months. Trading at $44.20 per share, Exelon stock ...

Desjardins Securities analyst Gary Ho sees TerraVest Industries Inc. ’s ( N/A ) US$546-million acquisition of EnTrans International as “transformative” and puts “an under-levered balance sheet to work ...

Two commonly prescribed medications to treat Alzheimer's are cholinesterase inhibitors (Aricept, Razadyne, Exelon) and ...

For people with mild to moderate Alzheimer’s, cholinesterase inhibitors like Aricept (donepezil), Exelon (rivastigmine), and Razadyne (galantamine) are typically used as first-line treatment. These ...

Shares of Exelon Co. (NASDAQ:EXC – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat Ratings reports.